April 17, 2024By Tamra SamiNeurotech’s NTI-164 meets endpoints in pediatric autism trialNeurotech International Ltd.’s cannabinoid NTI-164 met the primary and secondary endpoints in a phase II/III trial in children with autism spectrum disorder. The company also reported positive top-line data for Rett syndrome in a phase I/II trial.